Compare LGIH & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | EVO |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2013 | N/A |
| Metric | LGIH | EVO |
|---|---|---|
| Price | $47.64 | $3.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $75.90 | $7.00 |
| AVG Volume (30 Days) | ★ 360.1K | 47.1K |
| Earning Date | 04-28-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,705,504,000.00 | N/A |
| Revenue This Year | $2.32 | $1.37 |
| Revenue Next Year | $17.94 | $10.05 |
| P/E Ratio | $540.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.55 | $2.31 |
| 52 Week High | $69.42 | $4.42 |
| Indicator | LGIH | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 56.03 |
| Support Level | $45.69 | $2.88 |
| Resistance Level | $49.51 | $3.75 |
| Average True Range (ATR) | 2.37 | 0.07 |
| MACD | 0.38 | 0.01 |
| Stochastic Oscillator | 76.19 | 89.58 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.